Immusoft, a Seattle, WA-based biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells, has been awarded an up to $350k grant from the Thiel Foundation’s Breakout Labs.
Led by CEO Matthew Scholz, CSO Eric Herbig, and Vice President of Business Development Zach Hall, the company develops technology designed to re-program human immune cells to produce therapeutics in the body, which could dramatically improve the ability to treat a range of diseases, as well as enhance human health and longevity. Potential therapeutic applications of Immune System Programming (ISP™) technology include: HIV, enzyme replacement, autoimmune disorders, neurodegenerative disorders, infectious diseases, and maintenance therapy for cancers.
The core components of ISP™ technology were developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by the company.
FinSMEs
21/04/2012